Trial reportThe British journal of psychiatry : the journal of mental science2024
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.
Trial report in The British journal of psychiatry : the journal of mental science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.Clinical pharmacology and therapeutics · 2025Trial
- Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session.Psychopharmacology · 2026Article
- Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.Life (Basel, Switzerland) · 2026Review
- Personality changes following first-time psychedelic use in college students in Germany.Npj mental health research · 2026Article
- Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology.Journal of psychopharmacology (Oxford, England) · 2026Review
- Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.ACS pharmacology & translational science · 2026Review
- It's all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial.Palliative & supportive care · 2026Article
- Psychedelic therapy: a paradigm shift in treating neuropsychiatric disorders.Science China. Life sciences · 2025Article
- Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.Healthcare (Basel, Switzerland) · 2025Article
- Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co-Use: Results From the European Web Survey on Drugs.Drug and alcohol review · 2025Article
- Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Tabernanthalog, a Non-Hallucinogenic Psychedelic, Alleviates Cancer-Induced Cognitive Deficits via Serotonergic Pathways.International journal of molecular sciences · 2025Article
- New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?Pharmaceuticals (Basel, Switzerland) · 2025Review
- Further education in psychedelic-assisted therapy - experiences from Switzerland.BMC medical education · 2025Review
- Cumulative effects of stress-sensitivity factors on depressive symptoms and suicide risk: A prospective study.World journal of psychiatry · 2025Article
- Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program.Neuroscience applied · 2025Review
- Treatment of neuropathic pain with repeated low-dose MDMA: a case report.Frontiers in psychiatry · 2025Article
- Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnxiety disorders are a major public health burden with limited treatment options.
aimsWe investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness.
methodThis study was an
resultsParticipants reported a sustained reduction of STAI-G scores compared with baseline (least square means (95% CI) = -21.6 (-32.7, -10.4),
conclusionsPatients reported sustained long-term effects of LSD-assisted therapy for anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.